Sandoz, a Novartis division, has acquired the US distribution rights for daptomycin 500mg injection and fosaprepitant 150mg for injection from BE Pharmaceuticals AG, it was reported on Monday.

The rights have been acquired to reinforce the company's strategy to grow its injectable portfolio and overall offerings in the hospital setting. Daptomycin is a naturally occurring lipopeptide antibiotic used in the treatment of infections caused by Gram-positive bacteria and is the generic version of Cubicin. Fosaprepitant is an antiemetic drug used in the prevention of nausea and vomiting associated with certain chemotherapies, administered as IV infusion, and is the generic prodrug of Emend for injection. According to the distribution and supply agreements, Sandoz acquires the distribution rights in the United States for the two products from BE Pharmaceuticals AG, which retains responsibility for manufacturing the products and managing the regulatory approval process.